Version 1
: Received: 7 August 2023 / Approved: 8 August 2023 / Online: 9 August 2023 (02:48:16 CEST)
How to cite:
Yayan, J.; Franke, K.; Berger, M.; Windisch, W.; Rasche, K. Adhesion, Metastasis, and Inhibitor for Cancer Cells. Preprints2023, 2023080651. https://doi.org/10.20944/preprints202308.0651.v1
Yayan, J.; Franke, K.; Berger, M.; Windisch, W.; Rasche, K. Adhesion, Metastasis, and Inhibitor for Cancer Cells. Preprints 2023, 2023080651. https://doi.org/10.20944/preprints202308.0651.v1
Yayan, J.; Franke, K.; Berger, M.; Windisch, W.; Rasche, K. Adhesion, Metastasis, and Inhibitor for Cancer Cells. Preprints2023, 2023080651. https://doi.org/10.20944/preprints202308.0651.v1
APA Style
Yayan, J., Franke, K., Berger, M., Windisch, W., & Rasche, K. (2023). Adhesion, Metastasis, and Inhibitor for Cancer Cells. Preprints. https://doi.org/10.20944/preprints202308.0651.v1
Chicago/Turabian Style
Yayan, J., Wolfram Windisch and Kurt Rasche. 2023 "Adhesion, Metastasis, and Inhibitor for Cancer Cells" Preprints. https://doi.org/10.20944/preprints202308.0651.v1
Abstract
This comprehensive review delves into cancer's complexity, focusing on adhesion, metastasis, and inhibition. It explores the pivotal role of these factors in disease progression and therapeutic strategies. This review covers cancer cell migration, invasion, and colonization of distant organs, emphasizing the significance of cell adhesion and the intricate metastasis process. Inhibition approaches targeting adhesion molecules, such as integrins and cadherins, are discussed. Overall, this review contributes significantly to advancing cancer research and developing targeted therapies, holding promise for improving patient outcomes worldwide. Exploring different inhibition strategies revealed promising therapeutic targets to alleviate adhesion and metastasis of cancer cells. The effectiveness of integrin-blocking antibodies, small molecule inhibitors targeting FAK and the TGF-β pathway, and combination therapies underscores their potential to disrupt focal adhesions and control epithelial-mesenchymal transition processes. The identification of as FAK, Src, β-catenin and SMAD4 offers valuable starting points for further research and the development of targeted therapies. The complex interrelationships between adhesion and metastatic signaling networks will be relevant to the development of new treatment approaches.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
